These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11557115)

  • 1. Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas.
    Rodríguez-Salas N; Palacios J; Moreno G; de Castro J; González-Barón M; Gamallo C
    Lung Cancer; 2001 Oct; 34(1):67-74. PubMed ID: 11557115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer.
    Oshita F; Kameda Y; Hamanaka N; Saito H; Yamada K; Noda K; Mitsuda A
    Am J Clin Oncol; 2004 Jun; 27(3):215-9. PubMed ID: 15170136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.
    Hiraki A; Ueoka H; Yoshino T; Chikamori K; Onishi K; Kiura K; Bessho A; Mimoto J; Date H; Ando A; Shimizu N; Harada M
    Oncol Rep; 1999; 6(1):75-80. PubMed ID: 9864405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer.
    Paik KH; Park YH; Ryoo BY; Yang SH; Lee JC; Kim CH; Ki SS; Kim JM; Park MJ; Ahn HJ; Choi W; Chung JH
    J Korean Med Sci; 2006 Feb; 21(1):35-9. PubMed ID: 16479062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
    Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
    Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome.
    Gemba K; Ueoka H; Kiura K; Tabata M; Harada M
    Lung Cancer; 2000 Jul; 29(1):23-31. PubMed ID: 10880844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
    Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
    Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas.
    Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O
    Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome.
    Joseph MG; Banerjee D; Kocha W; Feld R; Stitt LW; Cherian MG
    Cancer; 2001 Aug; 92(4):836-42. PubMed ID: 11550155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
    Miyatake K; Gemba K; Ueoka H; Nishii K; Kiura K; Tabata M; Shibayama T; Takigawa N; Kawaraya M; Tanimoto M
    Anticancer Res; 2003; 23(3C):2829-36. PubMed ID: 12926120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates.
    Poupon MF; Arvelo F; Goguel AF; Bourgeois Y; Jacrot M; Hanania N; Arriagada R; Le Chevalier T
    J Natl Cancer Inst; 1993 Dec; 85(24):2023-9. PubMed ID: 7902445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant gene expression in small-cell lung cancer.
    Savaraj N; Wu CJ; Xu R; Lampidis T; Lai S; Donnelly E; Solomon J; Feun LG
    Am J Clin Oncol; 1997 Aug; 20(4):398-403. PubMed ID: 9256898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.
    Holzmayer TA; Hilsenbeck S; Von Hoff DD; Roninson IB
    J Natl Cancer Inst; 1992 Oct; 84(19):1486-91. PubMed ID: 1359152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
    Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
    Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and clinical significance of p53 protein and p21(WAF1) in non-small-cell lung carcinoma].
    Zhang H; Lü F; Yue W; Yan H; Deng L; Wang S
    Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):328-30. PubMed ID: 11866928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.